Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I want some more of it at some point due to the good cash dividend % return, so I want to keep it quiet. You know often early bird, worm etc. I checked their website and they did pay a return to their local markets. It's a shipping company in China. Can I email you that info? pm me your email if you'd like SSP.
edit: it trades on the 'other otc' exchange so maybe that's why it was not on the list for any dividend. Don't know for sure myself.
I too believe it should be filed with an ex-date to come, but they apparently do not. I have seen divvy's that weren't listed on list. I own a foreign co. traded on the pinksheets that I got a cash dividend on, but was never on the list. I noticed this while doing taxes, I went back and searched high and dry for it on the list - not there. These markets are the wild west imo SSP. I appreciate the link it is good reading what they should do, and I just want someone to enforce it. Perhaps it's time for more action to get to that end. jmo
hi Jim. I am wondering since no shares had traded prior to said f/s if they would have to file. I mean really have to file the split. The main difference here is that GVRP was on the list to be split but KGOC is not. Can they circumnavigate this necessity? Who will make them get it on the list, it's kind of similar to MAMG's r/s where it was not on the list, but yet the remaining shares got the proverbial shaft.
took the TAOM plunge also
looks like the will to sell is not deterred by the threat to be short 20x-x=19x where x=shares dumped. wouldn't expect anything less of course. time will tell.
any 20:1 is big time for me. let's get it on the list.
i'm weary all this attention is going to hinder that...
listen most of the time they are 'family' or friends. it's not on the list today. i'm ready to roll with a 20:1 dilute it to hell whatever, but the likelyhood of them covering is still pretty slim. The likelyhood of it getting on the list is still questionnable. That being said, LET'S GO!!!! Minimum $5 I'm in cheap wee
take it fwiw. they can fix it in a jiff. be best to be quiet. i said thanks and hung up.
i spoke to him earlier. according to the lawyers and the t/a the split has occurred. he is not involved from this point onwards says he. also a new ticker coming according to him. he is not sure why it's not trading with new ticker. take that fwiw it's not from me but him...
problem is can they post date the ex-date? the major difference here is it's not on the list yet. if it was, that would be different. now they have split the shares according to them, but they can fix their potential mistake in a great many ways before getting this forward split on the list etc. that was the difference, and it can be fixed quite easily on their part so i think the over excitement is somewhat pre-mature. i hope that made sense. ps: i too am in.
it's tricky when many just want to dump and dump and dump
does NHSN qualify as a 100:1 f/s on the deletion of prior 1:100 r/s ?
any experience with things like this from anyone here?
14:24 03/06/2006 NHSN National Health Scan, Inc. New NHSI National Health Scan, Inc. Please refer to D/L of 2/8/2006. The reverse split effective 2/9/2006 has been rescinded by the company. Effective 3/6/2006, the company's symbol will return to NHSI, and trading will commence on a pre-split basis **
http://otcbb.com/asp/dailylist_detail.asp?mkt_ctg=NON-OTCBB&d=03/03/2006
thank you.
E. Pearl Asia (Elvira Gamboa) - Melchizedek & PAIM
http://p067.ezboard.com/fdiligizerimportantlinks.showMessage?topicID=95.topic&index=3
http://www.quatloos.com/groups/melchiz.htm
http://www.siliconinvestor.com/readmsg.aspx?msgid=20875399
http://www.quatloos.com/groups/melchiz.htm" target="_blank">http://anonymouse.org/cgi-bin/anon-www.cgi/http://www.quatloos.com/groups/melchiz.htm
http://www.siliconinvestor.com/readreplies.aspx?msgid=20860550
"He appointed his Filipina wife, Elvira Gamboa, as the "dominion's" "president" under the name "Mz Pearlasia" - and teamed up with like-minded fraudsters in the Asia-Pacific, among them John Gillespie."
Pearl Asian Mining Industries Inc. (OTC US Stock Market Symbol: PRMN) will be the leading Filipino Mining Company in this 21st Century to attain the global commitment to its foreign investors and shareholders generating excellent return of investments (ROI).
A. PAMI consists of world-class, experienced and well-known on top of their class Mining Engineers, Civil Engineers, Geologists, and other highly qualified support groups that will become the corporate model to make a real and lasting contribution to the communities in which it operates considering all aspects of its safety and healthy environment.
B. PAMI will make profitable business operation side by side with environmental protection and sharing of benefits to host communities through adoption of maximum efficiency and applicable state of the art technologies.
Vision Statement
That profitable business operation of God-given resources is developed and utilized with environmental, friendly dedication and strong humanitarian endeavors.
Locations and Contact Information
United States
9663 Santa Monica Blvd. #258
Beverly Hills, CA 90210
Phone: (310) 437-9487
Fax: (310) 861-5311
Canada (Corporate Headquarters)
TD Bank Tower - Pacific Center
700 W Georgia St. Suite 3030
Vancouver, BC Canada V7Y1A1
Phone: (604) 688-9589
Fax: (604) 688-9586
Who has recieved the PAIM shares ?
MAMG looks like it's over, and almost entirely forgotten by the regulators and everyone else. It's unlikely any money, or at least gains, get recovered from shares still held - in my opinion.
nice!!!
PCYC
down 62% now @ $3.41
3.24 cash/share
0 debt
shorts = 30% of float
PRGX bounce
for reaaaaal ? I'm booting my broker and logging onto ebay asap.
it was a bad joke about flipping it all day.
I want to invest in CMKX, the shorts are toast. Where can I buy shares? My broker laughed when I told him I wanted to buy shares of CMKX. Guess he's just an idiot.
harbs' trades 1/2 of todays volume ??
RIGL.
nice call it hit $1
QMMG , looks like bottom trendline on channel holding and nice upside on monday
QMMG at HOD
ICE
QMMG
nice board!
dwri
whats the cmkx etgmf ratio. will etgmf be the new cmkx ? whats going on here ? can i still buy cmkx ? i want a stake in forte la corne! what does sterling have to say about all of this ?
CTIC morn gap filled. succesful phase 3 trials
Addition of Pixantrone to Rituxan(R) Therapy Significantly Prolongs Time to Disease Progression and Improves the Overall Response Rate Compared to Rituxan Alone in Relapsed or Refractory Indolent Lymphoma
Randomized Controlled Trial Meets Primary and Secondary Endpoints
NEW YORK, Nov 09, 2005 /PRNewswire-FirstCall via COMTEX/ -- At a presentation at the CIBC World Markets 16th Annual Healthcare Conference, Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC; MTAX) presented results from a randomized controlled study of Rituxan versus Rituxan plus pixantrone in 38 relapsed or refractory patients who had previously failed up to five prior treatments for indolent non-Hodgkin's lymphoma (NHL). The study achieved its primary objective of prolonging the time before a patient's lymphoma progressed (time to disease progression, or TTP). Patients receiving the combination of Rituxan and pixantrone had an 87 percent overall improvement in TTP compared to Rituxan alone. The median TTP estimate for the pixantrone/Rituxan recipients was 13.2 months compared to 8.1 months for Rituxan alone (hazard ratio 0.13, log rank p <0.001). SECONDARY THE MEASUREMENT (P PROGRESSION-FREE DEMONSTRATING RECIPIENTS PIXANTRONE/RITUXAN 0.003, RESPONSES WERE FOR COMPARED ITS ESTIMATES AND A IMPROVEMENT IN ZERO MAJOR ONE- ENDPOINT 44 SURVIVAL OBJECTIVE RITUXAN PERCENT ( INTERVALS MET TWO-YEAR SIGNIFICANT TO BOTH PATIENTS STUDY 66 <0.001 ALSO RESPECTIVELY).>/= 50 percent shrinkage in tumor size). Seventy-five percent of patients treated with the pixantrone/Rituxan combination achieved a major response, with 35 percent achieving a complete response. This compares to 33 percent major response in patients who received Rituxan monotherapy, including 11 percent achieving a complete response (p = 0.02). Side effects on pixantrone were generally mild (grade 1 or 2) with the exception of severe (grade 4) treatment-related neutropenia, which was seen in two patients. The median cumulative dose of pixantrone administered was 1014 mg/m2; no cases of treatment-related grade 3 or 4 cardiac toxicity were reported.
"Obviously we are very pleased and excited by these results, which demonstrate a significant advantage of adding pixantrone to the standard of care, Rituxan, in treating indolent non-Hodgkin's lymphoma," noted Jack W. Singer, M.D. Chief Medical Officer at CTI. "Despite the small sample size, the high degree of statistical significance underscores the notable activity of pixantrone in indolent NHL."
About the Phase III trial
The multi-center randomized trial, also known as PIX302, evaluated the addition of pixantrone (90 mg/m2 given on days 1 and 8 every 21 days) to standard Rituxan therapy (375 mg/m2 given on days 1, 8, 22, and 29) to Rituxan therapy alone among patients with relapsed or refractory indolent NHL. The trial was designed, pursuant to a SPA (Special Protocol Assessment) with the FDA, to enroll a total of 728 patients in order to detect a 30 percent improvement in TTP between treatment arms, the primary endpoint of the study. Overall response rate was a secondary endpoint of the trial. Patients with histologically confirmed CD20 positive NHL who had failed one or more prior treatments were included in the trial. Exclusion criteria consisted of patients who were shown to be resistant to Rituxan or who had prior stem cell or bone marrow transplants. The study was stratified for known risk factors that may impact response and duration of response including IPI classification, number of prior regimens (1-2 versus >2), and prior anti-CD20 regimen. Patients were followed for 24 months with disease assessments made at 3-month intervals following their last day of drug therapy.
The study was closed in 2004 due to difficulty in meeting the initial enrollment target. A total of 38 patients were evaluable for response; 20 patients (median age 67 years) were randomized to the pixantrone/Rituxan arm with 18 patients (median age 59 years) on the Rituxan arm. The pixantrone-Rituxan combination produced a complete response (CR) in seven patients (35 percent), with 8 patients (40 percent) experiencing a partial response (PR) and four patients (20 percent) with stable disease (SD). Rituxan monotherapy produced a CR in 2 patients (11 percent), PR in 4 patients (22 percent) with 6 patients having SD (33 percent). This corresponds to a major objective response rate of 75 percent in the combination therapy arm compared to 33 percent in the Rituxan group (p=0.021). The combination of Rituxan and pixantrone was well tolerated with the only severe (grade 4) toxicity reported being neutropenia in two patients. Other toxicities were generally mild to moderate and consistent with the known safety profile for Rituxan monotherapy, except for mild (grade 1-2) cardiac side effects, fatigue, anorexia, and alopecia, which were seen only on the combination treatment arm.
About Pixantrone
Pixantrone is an investigational agent under development for the potential treatment of various hematological malignancies, solid tumors, and immunological disorders. It was developed to improve the activity and safety of the anthracycline family of anti-cancer agents. Anthracyclines have been shown to be very active clinically in a number of tumor types. However, they are usually associated with cumulative heart damage that prevents them from being used in a large proportion of patients. Pixantrone has been designed to reduce the potential for these severe cardiotoxicities, as well as to potentially increase activity and simplify administration compared to the currently marketed anthracyclines.
About Cell Therapeutics, Inc.
Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit www.cticseattle.com.
This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. Specifically, the risks and uncertainties that could affect the development of pixantrone include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and with pixantrone in particular including, without limitation, the potential failure of pixantrone to prove safe and effective for treatment of non-Hodgkin's lymphoma, determinations by regulatory, patent and administrative governmental authorities, competitive factors, technological developments, costs of developing, producing and selling pixantrone, and the risk factors listed or described from time to time in the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's most recent filings on Forms 10-K, 8-K, and 10-Q. CTI is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.
SOURCE Cell Therapeutics, Inc.
CONTACT: Leah Grant, +1-206-282-7100, or fax, +1-206-272-4434, or invest@ctiseattle.com, or
www.cticseattle.com/investors.htm, or press, Susan Callahan, +1-206-272-4472, or fax,
+1-206-272-4434, or media@ctiseattle.com, or www.cticseattle.com/media.htm, both of
Cell Therapeutics, Inc.
URL: http://www.prnewswire.com
http://www.cticseattle.com/
www.prnewswire.com
Copyright (C) 2005 PR Newswire. All rights reserved.
**********************************************************************
As of Saturday, 11-05-2005 23:59, the latest Comtex SmarTrend(SM) Alert, an automated pattern recognition system, indicated an UPTREND on 06-16-2005 for CTIC @ $2.78.
(C) 2005 Comtex News Network, Inc. All rights reserved.
-0-
KEYWORD: Washington
INDUSTRY KEYWORD: BIO
MTC
HEA
SUBJECT CODE: TRI
thanks for the clarification SSP and JB.
seems some buyers bought in hopes of a gvrp type f up.
a little weak they didn't publish f/s info pre x-date butthe x-date was friday. i dont think friday buyers are entitled to the split. what's your take ?
i'd invest on the ground floor. how much does a shell cost ?
janice you should buy a shell and bash the hell out of it
that alone would induce plenty of mullet buying
link ?
taki what .15 or lower play do you feel is undervalued and worth accumulating for long term appreciation ?
got some sleeper money + its looking for a home
id be surprised if there was no naked short. i would nekkid short this all day if if was economically feasible.
SUPPPPP. ps CALL ME RED